Magnesium Glycinate and Human Evidence
Magnesium is an essential mineral. Magnesium glycinate is one delivery form, not a separate nutrient with automatically superior effects.
The amount to compare is elemental magnesium per labeled serving. Form, dose, baseline status, population, and outcome all affect what research can establish.
The quick read
-
Elemental amount comes first
A Supplement Facts panel declares elemental magnesium, not the total weight of the magnesium-containing compound. Serving size must be read separately.
-
The form name is not the whole specification
Glycinate, bisglycinate, chelation, buffering, carriers, and other magnesium sources require documentation; the words are not automatically interchangeable.
-
Sleep evidence remains uncertain
A 2026 systematic review found inconsistent results and low- to very-low-certainty evidence. It did not support routine oral magnesium treatment for insomnia.
Magnesium has essential roles—but that is not an outcome claim
Magnesium acts as a cofactor in hundreds of enzyme systems and contributes to energy production, protein and nucleic-acid synthesis, nerve and muscle function, glucose control, and blood-pressure regulation.
Those established roles do not mean that every person benefits from supplemental magnesium or that one form produces a specific feeling. Outcomes can depend on habitual intake, magnesium status, health condition, kidney function, dose, form, duration, and the endpoint measured.
Less than 1% of total body magnesium is in serum, and no single assessment method describes magnesium status satisfactorily in every context. A normal serum result does not always describe total stores, while nonspecific symptoms cannot diagnose deficiency.
What “magnesium glycinate” should tell you
In a bisglycinate chelate, magnesium is associated with glycine. The finished ingredient can still differ in chelation, buffering, carrier system, excipients, and exact nomenclature.
A product name alone cannot establish those details. Supplier specifications and fit-for-purpose analytical records define what material is present.
Four specifications to keep separate
-
Chelate identity
A name on a sheet does not by itself prove the intended chelate structure. Identity needs an appropriate specification and record.
-
Buffering
Some materials include magnesium oxide or another source. Buffered is not automatically good or bad, but “unbuffered” is a documentation-dependent claim.
-
Carrier and excipients
Flow agents, capsule materials, and other excipients affect the formula and serving size but are not the active mineral amount.
-
Naming
Glycinate, bisglycinate, chelated magnesium, and branded raw materials should not be treated as equivalent without supporting records.
Elemental magnesium and compound weight are different
A magnesium-containing compound includes magnesium plus the molecules associated with it. Only part of the total mass is magnesium.
On a U.S. Supplement Facts panel, the declared Magnesium amount is elemental magnesium per labeled serving. The source appears separately in parentheses, and Serving Size is its own field.
A front-panel number can otherwise refer to elemental amount, compound weight, a blend, a marketing name, one capsule, or a multi-capsule serving. Read all of those fields together.
Confirm how many capsules or other units make one labeled serving before comparing milligrams.
Read the milligrams on that row as elemental magnesium per serving. Do not substitute the total compound weight.
The parenthetical source identifies the form or forms. Directions determine use; a serving amount is not automatically a personalized daily recommendation.
Review other supplements and magnesium-containing medications when assessing combined supplemental intake.
What absorption research can—and cannot—say
Absorption varies with solubility, dose, baseline status, gastrointestinal conditions, formulation, and study method. Exposure is not the same as a meaningful human outcome.
A 2021 review found that organic formulations often appeared more bioavailable than inorganic formulations, but the underlying studies were heterogeneous. It did not establish glycinate as universally most absorbable.
Forms that dissolve well in liquid tend to be absorbed more completely than less-soluble forms.
Solubility alone cannot predict a clinical outcome.
That is a reasonable review-level summary when the heterogeneity is kept visible.
It does not mean every organic form is superior in every person.
A 1994 crossover trial compared 100 mg isotope-labeled magnesium diglycinate with magnesium oxide in 12 people after ileal resection. Overall absorption did not differ: 23.5% versus 22.8%.
A subgroup signal and better reported tolerance in this specialized population do not establish universal superiority or guaranteed gentleness in healthy adults.
Some forms and preparations may differ in gastrointestinal effects, but no magnesium form guarantees freedom from diarrhea, nausea, or cramping.
The evidence moved forward, but the conclusion remains narrow
Trials use different magnesium forms, elemental doses, populations, durations, and subjective or objective sleep measures. Those studies should not be compressed into a general sleep claim.
The most current synthesis identified possible modest benefits for selected subjective outcomes, but results were inconsistent and certainty remained low or very low.
Three randomized placebo-controlled trials included 151 older adults with insomnia. Pooled sleep-onset latency was shorter, while total sleep time did not improve significantly.
Risk of bias was moderate to high and certainty was low to very low. The studies evaluated oral magnesium broadly, not one glycinate product.
A four-week trial randomized 155 adults reporting poor sleep to 250 mg/day elemental magnesium from magnesium bisglycinate or placebo. Insomnia Severity Index scores decreased by 3.9 points with magnesium and 2.3 with placebo; the adjusted between-group result was p = 0.049 with a small effect size, Cohen’s d = 0.2.
Other psychological outcomes did not differ significantly. Sleep was self-reported, follow-up was short, baseline status was not robustly measured, and a commercial research relationship was disclosed.
The review included 12 randomized trials in its main sleep synthesis and three additional movement- or cramp-related sleep-disturbance trials. Populations, formulations, elemental doses, durations, and measures varied substantially.
Findings were inconsistent across subjective outcomes, EEG, actigraphy, consumer-wearable estimates, and physiological markers. Certainty was low to very low, and the authors concluded that current evidence does not support oral magnesium as a routine treatment for insomnia.
Some adults may experience modest changes in selected subjective sleep outcomes, but the evidence does not establish an optimal form, dose, or duration; routine insomnia treatment; a guaranteed result; form superiority; or an outcome for the finished REVESYN product.
Intake, status, and population change the answer
-
Recommended intake is total intake
U.S. adult RDAs range from 310 to 420 mg/day by age and sex and include food, beverages, and supplements. They are not universal supplement doses.
-
The UL has a different boundary
The adult UL is 350 mg/day from supplements and medications, excludes food magnesium, and is based mainly on gastrointestinal effects. It is not an efficacy target.
-
Baseline context matters
Low dietary intake, gastrointestinal conditions, medicines, diagnosed deficiency, and kidney function create different evidence and safety contexts.
-
Study dose is not label advice
A research dose belongs to its tested material, schedule, duration, and population. More is not automatically better.
Kidney function, total intake, and medicines matter
Open each item for the main safety boundaries. This general information cannot replace individualized guidance or the final product label.
Higher supplemental and medication-derived magnesium intakes can cause diarrhea, nausea, and abdominal cramping. No form guarantees tolerance.
Risk of toxicity rises when kidney function is impaired because magnesium clearance can fall. Severe excess can cause low blood pressure, lethargy, weakness, breathing difficulty, and abnormal heart rhythm.
People with kidney disease should not self-direct magnesium supplementation.
Magnesium can reduce absorption of oral bisphosphonates and form complexes with tetracycline and quinolone antibiotics. Diuretics and long-term proton-pump inhibitor use can also affect magnesium status.
Follow the medicine label and ask a pharmacist or prescribing clinician how to separate doses. Ask a qualified professional before use if you take medicines, are pregnant or breastfeeding, have a medical condition, or combine multiple magnesium products.
What the evidence does not establish
Current evidence does not establish that magnesium glycinate is the best, most absorbable, or universally preferred form; guarantees absorption, tolerance, relaxation, or sleep; or treats insomnia, anxiety, depression, cramps, migraine, or another condition.
- Essential nutrient biology does not prove that supplementation improves a function in someone with adequate intake.
- Compound weight cannot replace elemental magnesium when comparing a dose.
- The words glycinate or bisglycinate do not prove unbuffered, fully chelated, or oxide-free material.
- One trial does not establish an optimal general-wellness dose.
- Ingredient research does not make a finished REVESYN product clinically tested.
Nutrient function, dietary adequacy, biochemical status, absorption, symptom scores, and disease treatment are separate evidence levels.
Verified label facts are not clinical evidence
REVESYN Magnesium Glycinate declares 275 mg of elemental magnesium per labeled three-capsule serving. The corresponding magnesium glycinate source-compound amount is 2,500 mg per serving. The bottle contains 90 capsules, equal to 30 labeled servings.
These are label and formula facts, not evidence that the product is the most absorbable form, produces a sleep outcome, or matches a study preparation. Serving amount is not personalized advice, and the product card below is a neutral navigation destination.
Available supplier or historical analytical documentation answers only the specific identity or quality question described in that record. It does not by itself prove current-lot status, every-batch verification, finished-product label strength, clinical testing, or an outcome.
Related product
Magnesium glycinate FAQ
These answers preserve the distinction between label facts, ingredient evidence, and individualized use.
For REVESYN, 275 mg is the declared elemental magnesium per three-capsule serving. The magnesium glycinate source-compound amount is separately recorded as 2,500 mg per serving.
No. Comparative evidence is heterogeneous, and direct diglycinate data are narrow. Form names also do not settle chelation, buffering, carrier, or finished-product quality.
Current randomized-trial evidence is inconsistent and low to very low certainty. The 2026 systematic review did not support oral magnesium as a routine treatment for insomnia.
People with kidney disease, prescription medicines, pregnancy or breastfeeding, a medical condition, or multiple magnesium sources should seek individualized guidance. Persistent sleep problems also deserve clinical evaluation.
Continue through the evidence library
-
Magnesium foundations
Review essential nutrient biology without converting it into a supplement outcome.
-
Cellular energy
See where magnesium participates in ATP-related biology and where that map stops.
-
Testing & Verification
Learn what identity and quality records can—and cannot—establish.
-
Science glossary
Definitions for elemental dose, bioavailability, biomarkers, endpoints, and study design.
How to read this review
REVESYN separates essential nutrient biology, elemental amount, material identity, exposure, and measured human outcomes. Positive findings remain tied to the tested form, dose, population, duration, and endpoint.
Evidence review updated September 16, 2026, including the 2026 adult-sleep systematic review. Official NIH ODS, FDA, and FTC pages rechecked September 16, 2026.
Educational information only; not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent disease.
Selected references
The sources below support the label-reading, absorption, human-outcome, safety, and regulatory boundaries used on this page.
NIH Office of Dietary Supplements. Magnesium — Health Professional Fact Sheet. Official page rechecked September 16, 2026.
Supports physiology, label interpretation, intake references, adverse effects, kidney-risk context, and medication interactions; it is not product-specific evidence.
Pardo MR, Garicano Vilar E, San Mauro Martín I, Camina Martín MA. Bioavailability of magnesium food supplements: A systematic review. Nutrition. 2021;89:111294. PMID 34111673.
The included studies differed in forms, populations, doses, and measurement methods; the review does not establish glycinate as universally superior.
Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN. 1994;18(5):430–435. PMID 7815675.
A 12-person specialized clinical population cannot establish universal absorption or tolerability in healthy adults.
Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complement Med Ther. 2021;21:125. PMID 33865376.
The review found low- to very-low-certainty evidence from three small trials in older adults and did not evaluate one glycinate product.
Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nat Sci Sleep. 2025;17:2027–2040. PMID 40918053.
The four-week study reported a small self-reported insomnia-score effect; it does not establish insomnia treatment or an outcome for the REVESYN product.
Lopresti AL, Smith SJ, Drummond PD. Magnesium Supplementation for Sleep in Adults: A Systematic Review of Randomized Controlled Trials. J Diet Suppl. 2026;23(5):553–581. PMID 42661485.
Across 12 main sleep trials, findings were inconsistent and certainty was low to very low; the review did not support routine magnesium treatment for insomnia.
U.S. Federal Trade Commission. Health Products Compliance Guidance. 2022.
Supports the substantiation and implied-claim boundaries used on this page.
U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. Official page rechecked September 16, 2026.
Supports the general regulatory boundary; it is not an approval of this product or its claims.
NIH Office of Dietary Supplements. Frequently Asked Questions: Dietary Supplement Labels. Official page rechecked September 16, 2026.
Supports serving-size and ingredient-amount reading context.
